Compare VHC & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VHC | IFRX |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.7M | 86.0M |
| IPO Year | 1999 | 2017 |
| Metric | VHC | IFRX |
|---|---|---|
| Price | $18.67 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 15.5K | ★ 7.7M |
| Earning Date | 11-14-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $106,000.00 | $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,075.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2020.00 | N/A |
| 52 Week Low | $3.68 | $0.71 |
| 52 Week High | $29.00 | $2.82 |
| Indicator | VHC | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.68 | 42.21 |
| Support Level | $18.13 | $0.92 |
| Resistance Level | $23.70 | $1.28 |
| Average True Range (ATR) | 1.89 | 0.11 |
| MACD | -0.63 | -0.02 |
| Stochastic Oscillator | 5.52 | 30.42 |
VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.